This article was originally published in Start Up
ReVas Inc. believes that vasectomy would be a more desirable form of permanent birth control if men knew that the procedure could be easily reversed. The company aims to develop such a method, inserting a nylon stent into the vas deferens to prevent sperm passage, with a portion left outside the vas for venting and to facilitate removal.
You may also be interested in...
Given the huge impact that having a baby has on every aspect of a woman's life--and that of her mate--it's small wonder that a growing number of companies are aiming to offer Baby Boomers improved contraceptive choices. Some are developing devices to make the widely performed tubal ligation surgery, which renders women sterile, less invasive, more convenient and safer than it has been to date. At least one firm hopes to give men a chance to participate in family planning via reversible vasectomization.
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III program for epaminurad, while LG Chem has recently submitting an application for a new Phase III trial with its contender tigulixostat.
Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.